CY1110376T1 - Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος - Google Patents
Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματοςInfo
- Publication number
- CY1110376T1 CY1110376T1 CY20081100507T CY081100507T CY1110376T1 CY 1110376 T1 CY1110376 T1 CY 1110376T1 CY 20081100507 T CY20081100507 T CY 20081100507T CY 081100507 T CY081100507 T CY 081100507T CY 1110376 T1 CY1110376 T1 CY 1110376T1
- Authority
- CY
- Cyprus
- Prior art keywords
- asthma
- budesonide
- prevent
- composition including
- therapeutic immunity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται στη χρήση μίας σύνθεσης για συμπτωματική ανακούφιση, όταν χρειαστεί, που περιλαμβάνει, σε πρόσμιξη, (α) ένα πρώτο δραστικό συστατικό, το οποίο είναι φορμοτερόλη, ένα φαρμακευτικώς αποδεκτό άλας ή επιδιαλυτωμένο σύμπλοκο αυτής ή ένα επιδιαλυτωμένο σύμπλοκο ενός τέτοιου άλατος· και (β) ένα δεύτερο δραστικό συστατικό, το οποίο είναι βουδεσονίδη· για την παρασκευή ενός φαρμάκου για χρήση στην πρόληψη από ή τη θεραπευτική αντιμετώπιση μίας οξείας κατάστασης άσθματος και/ή διαλείποντος άσθματος και/ή επεισοδίων σε χρόνιο άσθμα. Η εφεύρεση αναφέρεται περαιτέρω σε μία μέθοδο για την πρόληψη από ή τη θεραπευτική αντιμετώπιση μίας οξείας κατάστασης άσθματος και/ή διαλείποντος άσθματος και/ή επεισοδίων σε χρόνιο άσθμα χορηγώντας, με εισπνοή, μία σύνθεση που περιλαμβάνει τα πρώτο και δεύτερο δραστικά συστατικά, όπως ορίστηκαν προηγουμένως.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802073A SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | New use |
| EP99930103A EP1085877B1 (en) | 1998-06-11 | 1999-06-10 | Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110376T1 true CY1110376T1 (el) | 2015-04-29 |
Family
ID=20411658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100507T CY1110376T1 (el) | 1998-06-11 | 2008-05-13 | Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20010049396A1 (el) |
| EP (3) | EP1316311A1 (el) |
| JP (1) | JP2002517450A (el) |
| KR (1) | KR20010052721A (el) |
| CN (1) | CN100389771C (el) |
| AR (1) | AR018410A1 (el) |
| AT (1) | ATE389409T1 (el) |
| AU (1) | AU771715B2 (el) |
| BR (1) | BR9911073A (el) |
| CA (1) | CA2334411C (el) |
| CY (1) | CY1110376T1 (el) |
| CZ (1) | CZ300874B6 (el) |
| DE (1) | DE69938390T2 (el) |
| DK (1) | DK1085877T3 (el) |
| EE (1) | EE05661B1 (el) |
| ES (1) | ES2302384T3 (el) |
| HK (1) | HK1035145A1 (el) |
| HU (1) | HUP0103108A3 (el) |
| ID (1) | ID27937A (el) |
| IL (2) | IL139921A0 (el) |
| IS (1) | IS5752A (el) |
| MY (1) | MY129281A (el) |
| NO (3) | NO20006253L (el) |
| NZ (1) | NZ536279A (el) |
| PL (1) | PL344665A1 (el) |
| PT (1) | PT1085877E (el) |
| RU (1) | RU2222332C2 (el) |
| SA (1) | SA99200234B1 (el) |
| SE (1) | SE9802073D0 (el) |
| SK (1) | SK286252B6 (el) |
| TR (1) | TR200003666T2 (el) |
| TW (1) | TWI252756B (el) |
| UA (1) | UA87956C2 (el) |
| WO (1) | WO1999064014A1 (el) |
| ZA (1) | ZA200006943B (el) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| GB0009584D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
| IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| GB0012261D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| ME00220B (me) | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom |
| EP1273292B1 (en) | 2001-07-02 | 2004-05-26 | CHIESI FARMACEUTICI S.p.A. | Optimised formulation of tobramycin for aerosolization |
| GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| DE60227691D1 (de) * | 2001-11-01 | 2008-08-28 | Nektar Therapeutics | Sprühtrocknungsverfahren |
| FI20020126A0 (fi) * | 2002-01-23 | 2002-01-23 | Orion Corp | Koostumuksia pulmonaaliseen antoon |
| SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
| JP4744876B2 (ja) * | 2002-08-21 | 2011-08-10 | ノートン・ヘルスケアー リミテッド | 乾燥粉末吸入組成物の製造方法 |
| GB0219511D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Method of preparing dry powder inhalation compositions |
| GB0219512D0 (en) * | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| US20070098644A1 (en) * | 2005-10-31 | 2007-05-03 | Richie's Pharmacy And Medical Supply, Incorporated | Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease |
| GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
| CA2677838C (en) | 2007-02-11 | 2017-08-01 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
| EP2327403A3 (en) | 2007-02-19 | 2011-08-31 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators |
| EP1982709A1 (en) | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| TWI695723B (zh) | 2009-05-29 | 2020-06-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 |
| DK2538922T3 (en) * | 2010-02-25 | 2016-07-04 | Andi-Ventis Ltd | The formulation of compositions for the treatment of inflammatory conditions |
| RU2568882C2 (ru) * | 2010-07-16 | 2015-11-20 | Сипла Лимитед | Фармацевтические композиции |
| WO2012030647A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| US9061352B2 (en) | 2010-08-30 | 2015-06-23 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| CN102416179B (zh) | 2010-09-28 | 2014-05-07 | 益得生物科技股份有限公司 | 用于哮喘的吸入性复方组合物 |
| WO2012050945A1 (en) | 2010-09-29 | 2012-04-19 | Pulmatrix, Inc. | Cationic dry powders |
| WO2012044736A1 (en) | 2010-09-29 | 2012-04-05 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| NZ629722A (en) | 2012-02-29 | 2017-03-31 | Pulmatrix Operating Co Inc | Inhalable dry powders |
| RU2504382C1 (ru) * | 2012-06-13 | 2014-01-20 | Шолекс Девелопмент Гмбх | Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения |
| JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス，インコーポレイテッド | チオトロピウム乾燥粉末 |
| ITMI20130571A1 (it) | 2013-04-10 | 2014-10-11 | Zambon Spa | Composizione farmaceutica contenente budesonide e formoterolo |
| GB201408387D0 (en) * | 2014-05-12 | 2014-06-25 | Teva Pharmaceuticals Europ B V | Treatment of respiratory disorders |
| WO2017108917A1 (en) * | 2015-12-22 | 2017-06-29 | Astrazeneca Ab | Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease |
| IT202000006442A1 (it) * | 2020-03-27 | 2021-09-27 | Genetic S P A | Budesonide 21-phosphate salts and pharmaceutical compositions containing the same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203401A (en) | 1979-01-29 | 1980-05-20 | General Motors Corporation | Evaporative emissions canister |
| IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| FR2651678B1 (fr) | 1989-09-08 | 1992-04-30 | Glaxo Group Ltd | Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone. |
| US5250286A (en) * | 1990-05-07 | 1993-10-05 | Aegis Technology, Inc. | Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline |
| PL164294B1 (pl) | 1990-12-20 | 1994-07-29 | Inst Farmaceutyczny | Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL |
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5119791A (en) | 1991-06-07 | 1992-06-09 | General Motors Corporation | Vapor storage canister with liquid trap |
| US5444521A (en) | 1991-07-15 | 1995-08-22 | Canon Kabushiki Kaisha | Image fixing device capable of controlling heating overshoot |
| DE69232462T2 (de) * | 1991-12-18 | 2002-10-10 | Astrazeneca Ab | Formoterol und budesonide enthaltende zusammensetzung |
| EP0613371B1 (en) | 1991-12-18 | 2002-03-06 | AstraZeneca AB | New combination of formoterol and budesonide |
| US5408977A (en) | 1993-08-23 | 1995-04-25 | Walbro Corporation | Fuel tank with carbon canister and shut-off valve |
| WO1995009615A1 (en) | 1993-10-01 | 1995-04-13 | Astra Aktiebolag | Process i |
| SE9404080L (sv) * | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US5511957A (en) | 1994-09-27 | 1996-04-30 | Walbro Corporation | High capacity fuel pump and filter combination |
| US5983956A (en) * | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| SE9700134D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| GB9519692D0 (en) * | 1995-09-27 | 1995-11-29 | Quillin Helen | Atomising nozzle |
| IL124522A0 (en) | 1995-11-24 | 1998-12-06 | Smithkline Beecham Spa | Quinoline derivatives |
| US5651349A (en) | 1995-12-11 | 1997-07-29 | Chrysler Corporation | Purge system flow monitor and method |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| WO1999000134A1 (en) | 1997-06-27 | 1999-01-07 | Astra Aktiebolag (Publ) | New combination of antiasthma medicaments |
| SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| US5957114A (en) | 1998-07-17 | 1999-09-28 | Ford Motor Company | Evaporative emission canister for an automotive vehicle |
| US5924410A (en) | 1998-07-20 | 1999-07-20 | Ford Motor Company | Evaporative emission canister for an automotive vehicle |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| US6227862B1 (en) * | 1999-02-12 | 2001-05-08 | Advanced Drivers Education Products And Training, Inc. | Driver training system |
| DE60016990T2 (de) | 1999-02-26 | 2005-12-29 | Walbro Corp., Cass City | Fahrzeugbrennstoffsystem |
| SE9900834D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| US6237574B1 (en) | 1999-04-20 | 2001-05-29 | Ford Motor Company | Evaporative emission canister for an automotive vehicle |
| US6136075A (en) | 1999-05-03 | 2000-10-24 | Westvaco Corporation | Automotive evaporative emissions canister adsorptive restraint system |
| JP3646217B2 (ja) | 1999-07-08 | 2005-05-11 | 愛三工業株式会社 | キャニスタモジュール |
| US6374811B1 (en) | 2000-10-04 | 2002-04-23 | Ford Global Technologies, Inc. | System and method for minimizing fuel evaporative emissions from an internal combustion engine |
-
1998
- 1998-06-11 SE SE9802073A patent/SE9802073D0/xx unknown
-
1999
- 1999-05-28 AR ARP990102532A patent/AR018410A1/es unknown
- 1999-06-01 TW TW088109070A patent/TWI252756B/zh not_active IP Right Cessation
- 1999-06-09 SA SA99200234A patent/SA99200234B1/ar unknown
- 1999-06-09 MY MYPI99002351A patent/MY129281A/en unknown
- 1999-06-10 AT AT99930103T patent/ATE389409T1/de active
- 1999-06-10 NZ NZ536279A patent/NZ536279A/en not_active IP Right Cessation
- 1999-06-10 EP EP03002381A patent/EP1316311A1/en not_active Withdrawn
- 1999-06-10 JP JP2000553082A patent/JP2002517450A/ja active Pending
- 1999-06-10 PT PT99930103T patent/PT1085877E/pt unknown
- 1999-06-10 UA UA2000126983A patent/UA87956C2/uk unknown
- 1999-06-10 EE EEP200000740A patent/EE05661B1/xx unknown
- 1999-06-10 CZ CZ20004593A patent/CZ300874B6/cs not_active IP Right Cessation
- 1999-06-10 HU HU0103108A patent/HUP0103108A3/hu unknown
- 1999-06-10 TR TR2000/03666T patent/TR200003666T2/xx unknown
- 1999-06-10 EP EP99930103A patent/EP1085877B1/en not_active Revoked
- 1999-06-10 BR BR9911073-3A patent/BR9911073A/pt not_active Application Discontinuation
- 1999-06-10 IL IL13992199A patent/IL139921A0/xx active IP Right Grant
- 1999-06-10 ID IDW20002566A patent/ID27937A/id unknown
- 1999-06-10 US US09/367,950 patent/US20010049396A1/en not_active Abandoned
- 1999-06-10 PL PL99344665A patent/PL344665A1/xx unknown
- 1999-06-10 WO PCT/SE1999/001031 patent/WO1999064014A1/en not_active Application Discontinuation
- 1999-06-10 RU RU2000131218/14A patent/RU2222332C2/ru not_active IP Right Cessation
- 1999-06-10 CN CNB998072303A patent/CN100389771C/zh not_active Expired - Lifetime
- 1999-06-10 AU AU46710/99A patent/AU771715B2/en not_active Expired
- 1999-06-10 EP EP10178172A patent/EP2266574A1/en not_active Withdrawn
- 1999-06-10 CA CA002334411A patent/CA2334411C/en not_active Expired - Lifetime
- 1999-06-10 ES ES99930103T patent/ES2302384T3/es not_active Expired - Lifetime
- 1999-06-10 SK SK1888-2000A patent/SK286252B6/sk not_active IP Right Cessation
- 1999-06-10 KR KR1020007013993A patent/KR20010052721A/ko not_active Application Discontinuation
- 1999-06-10 DK DK99930103T patent/DK1085877T3/da active
- 1999-06-10 DE DE69938390T patent/DE69938390T2/de not_active Expired - Lifetime
-
2000
- 2000-11-27 ZA ZA200006943A patent/ZA200006943B/en unknown
- 2000-11-27 IL IL139921A patent/IL139921A/en not_active IP Right Cessation
- 2000-12-05 IS IS5752A patent/IS5752A/is unknown
- 2000-12-08 NO NO20006253A patent/NO20006253L/no not_active Application Discontinuation
-
2001
- 2001-08-17 HK HK01105814A patent/HK1035145A1/xx not_active IP Right Cessation
-
2003
- 2003-09-19 US US10/665,240 patent/US9295644B2/en not_active Expired - Lifetime
-
2008
- 2008-05-13 CY CY20081100507T patent/CY1110376T1/el unknown
-
2013
- 2013-02-18 NO NO20130269A patent/NO20130269L/no not_active Application Discontinuation
-
2014
- 2014-06-27 NO NO20140823A patent/NO20140823L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110376T1 (el) | Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος | |
| CA2503810A1 (en) | Therapeutic agent for fibromyalgia | |
| ID29181A (id) | Kombinasi formoterol dan garam tiotropium | |
| AR022090A1 (es) | PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN | |
| BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
| CY1109661T1 (el) | 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης | |
| ATE495793T1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
| CY1107465T1 (el) | Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων | |
| SE9901573D0 (sv) | New compounds | |
| ATE287267T1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
| PT1383752E (pt) | 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos | |
| SE9704644D0 (sv) | New use | |
| ATE429925T1 (de) | Methoden und pharmazeutische zusammensetzungen zur wundheilung | |
| NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
| TW200503683A (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| SE9901572D0 (sv) | New compounds | |
| ATE298240T1 (de) | Getrennte dosis therapien mit gefässschädigender aktivität | |
| HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
| CY1106129T1 (el) | Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος | |
| KR910004190A (ko) | 온단세트론의 신규 의학 용도 | |
| DE60235965D1 (de) | Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz | |
| KR930702016A (ko) | 골다공증 치료제 | |
| UA144734U (uk) | Спосіб лікування вірусних інфекційних захворювань | |
| KR940002268A (ko) | 21-클로로-프레그난 유도체 | |
| BR0205625C1 (pt) | Formulações nasais em gel |